Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 712 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish... May 5, 2026 Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen... July 29, 2022 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 Do as I say, not as I do – when the... July 13, 2021 Load more HOT NEWS Woman, 88, Had Been Waving from Her Window for Over a... High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response 7 Practical Tips for Taking Long-Term Medication
